JAMA otolaryngology-- head & neck surgery最新文献

筛选
英文 中文
Oropharyngeal Necrotizing Fasciitis in a Previously Healthy Patient. 一名健康患者的口咽坏死性筋膜炎
IF 6 1区 医学
JAMA otolaryngology-- head & neck surgery Pub Date : 2024-11-27 DOI: 10.1001/jamaoto.2024.3987
Oleksandr Butskiy, Gina Trinh
{"title":"Oropharyngeal Necrotizing Fasciitis in a Previously Healthy Patient.","authors":"Oleksandr Butskiy, Gina Trinh","doi":"10.1001/jamaoto.2024.3987","DOIUrl":"https://doi.org/10.1001/jamaoto.2024.3987","url":null,"abstract":"","PeriodicalId":14632,"journal":{"name":"JAMA otolaryngology-- head & neck surgery","volume":" ","pages":""},"PeriodicalIF":6.0,"publicationDate":"2024-11-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142728683","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Lobectomy vs Total Thyroidectomy With Ipsilateral Lateral Neck Dissection for N1b Intermediate-Risk Papillary Thyroid Carcinoma. N1b中危甲状腺乳头状癌的甲状腺叶切除术与全甲状腺切除术加同侧颈部切除术的比较
IF 6 1区 医学
JAMA otolaryngology-- head & neck surgery Pub Date : 2024-11-27 DOI: 10.1001/jamaoto.2024.3860
Yoshiyuki Saito, Kenichi Matsuzu, Amr H Abdelhamid Ahmed, Kosuke Inoue, Hiroshi Shibuya, Ai Matsui, Yoko Kuga, Reiko Ono, Kana Yoshioka, Chie Masaki, Junko Akaishi, Kiyomi Y Hames, Ritsuko Okamura, Chisato Tomoda, Akifumi Suzuki, Wataru Kitagawa, Mitsuji Nagahama, Kiminori Sugino, Hiroshi Takami, Gregory W Randolph, Koichi Ito
{"title":"Lobectomy vs Total Thyroidectomy With Ipsilateral Lateral Neck Dissection for N1b Intermediate-Risk Papillary Thyroid Carcinoma.","authors":"Yoshiyuki Saito, Kenichi Matsuzu, Amr H Abdelhamid Ahmed, Kosuke Inoue, Hiroshi Shibuya, Ai Matsui, Yoko Kuga, Reiko Ono, Kana Yoshioka, Chie Masaki, Junko Akaishi, Kiyomi Y Hames, Ritsuko Okamura, Chisato Tomoda, Akifumi Suzuki, Wataru Kitagawa, Mitsuji Nagahama, Kiminori Sugino, Hiroshi Takami, Gregory W Randolph, Koichi Ito","doi":"10.1001/jamaoto.2024.3860","DOIUrl":"https://doi.org/10.1001/jamaoto.2024.3860","url":null,"abstract":"<p><strong>Importance: </strong>The management of papillary thyroid carcinoma (PTC), particularly in cases with clinically apparent lateral neck lymph node metastasis (cN1b), remains an area of debate. The surgical options for PTC, including total thyroidectomy and lobectomy, have distinct impacts on patients' outcomes and quality of life.</p><p><strong>Objective: </strong>To compare survival and recurrence outcomes between patients who underwent a lobectomy plus ipsilateral lateral neck dissection (LND) and those who underwent a total thyroidectomy plus ipsilateral LND for intermediate-risk cN1b PTC with both primary tumors and lymph node metastases in the ipsilateral neck region.</p><p><strong>Design, setting, and participants: </strong>This retrospective cohort study was conducted at Ito Hospital, Tokyo, Japan. Patients who underwent surgery for PTC between January 2005 and December 2012 were included, and those with high-risk PTCs and concurrent other thyroid cancers were excluded. Data were analyzed from April to August 2024.</p><p><strong>Exposures: </strong>Lobectomy plus LND vs total thyroidectomy plus LND.</p><p><strong>Main outcomes and measures: </strong>An inverse probability of treatment weighting (IPTW)-adjusted Kaplan-Meier analysis and a Cox proportional hazards regression analysis were performed to compare the patients' overall survival, recurrence-free survival (RFS), and modified RFS (which considered the potential need for a future contralateral lobectomy).</p><p><strong>Results: </strong>Of 401 included patients, 317 (79.1%) were female, and the median (IQR) age was 47 (36-59) years. A total of 157 patients underwent lobectomy plus ipsilateral LND and 244 underwent total thyroidectomy plus ipsilateral LND. The median (IQR) follow-up time was 13.0 (11.2-15.0) years. The IPTW-adjusted overall survival rates at 5, 10, and 15 years were 98.0% (95% CI, 93.9-99.3), 97.5% (95% CI, 93.2-99.1), and 96.8% (95% CI, 92.2-98.7), respectively, for the lobectomy group vs 99.4% (95% CI, 97.0-99.9), 97.4% (95% CI, 94.4-98.8), and 96.9% (95% CI, 93.3-98.5), respectively, for the total thyroidectomy group (hazard ratio [HR], 1.10; 95% CI, 0.35-3.47). The IPTW-adjusted RFS rates at 5, 10, and 15 years were 93.8% (95% CI, 88.5-96.7), 88.4% (95% CI, 82.0-92.6), and 84.1% (95% CI, 76.8-89.3), respectively, for the lobectomy group vs 95.4% (95% CI, 91.8-97.4), 92.9% (95% CI, 88.8-95.5), and 87.8% (95% CI, 80.8-92.4), respectively, for the total thyroidectomy group (HR, 1.41; 95% CI, 0.79-2.54). The IPTW-adjusted modified RFS rates at 5, 10, and 15 years were 96.7% (95% CI, 92.2-98.6), 93.8% (95% CI, 88.5-96.7), and 88.9% (95% CI, 82.4-93.1), respectively, for the lobectomy group vs 95.4% (95% CI, 91.8-97.4), 92.9% (95% CI, 88.8-95.5), and 87.8% (95% CI, 80.8-92.4), respectively, for the total thyroidectomy group (HR, 0.93; 95% CI, 0.49-1.76).</p><p><strong>Conclusions and relevance: </strong>In this study, for these selected intermediate-risk cN1b P","PeriodicalId":14632,"journal":{"name":"JAMA otolaryngology-- head & neck surgery","volume":" ","pages":""},"PeriodicalIF":6.0,"publicationDate":"2024-11-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142728678","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Firm Gingival Enlargement in the Anterior Maxilla. 上颌前部坚固的牙龈增生
IF 6 1区 医学
JAMA otolaryngology-- head & neck surgery Pub Date : 2024-11-27 DOI: 10.1001/jamaoto.2024.4012
Michael Schiappa, Molly Housley Smith, Nicholas F Callahan
{"title":"Firm Gingival Enlargement in the Anterior Maxilla.","authors":"Michael Schiappa, Molly Housley Smith, Nicholas F Callahan","doi":"10.1001/jamaoto.2024.4012","DOIUrl":"https://doi.org/10.1001/jamaoto.2024.4012","url":null,"abstract":"","PeriodicalId":14632,"journal":{"name":"JAMA otolaryngology-- head & neck surgery","volume":" ","pages":""},"PeriodicalIF":6.0,"publicationDate":"2024-11-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142728740","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Immune Checkpoint Inhibitors for Head and Neck Squamous Cell Carcinoma. 免疫检查点抑制剂治疗头颈部鳞状细胞癌
IF 6 1区 医学
JAMA otolaryngology-- head & neck surgery Pub Date : 2024-11-27 DOI: 10.1001/jamaoto.2024.3966
Hui-Chin Chang, Shuo-Yan Gau
{"title":"Immune Checkpoint Inhibitors for Head and Neck Squamous Cell Carcinoma.","authors":"Hui-Chin Chang, Shuo-Yan Gau","doi":"10.1001/jamaoto.2024.3966","DOIUrl":"https://doi.org/10.1001/jamaoto.2024.3966","url":null,"abstract":"","PeriodicalId":14632,"journal":{"name":"JAMA otolaryngology-- head & neck surgery","volume":" ","pages":""},"PeriodicalIF":6.0,"publicationDate":"2024-11-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142728744","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Polygenic Score for Clinicopathologic Features and Survival Outcomes in Papillary Thyroid Carcinoma. 甲状腺乳头状癌临床病理特征和生存结果的多基因评分
IF 6 1区 医学
JAMA otolaryngology-- head & neck surgery Pub Date : 2024-11-27 DOI: 10.1001/jamaoto.2024.3963
Sophie Li, Guibin Zheng, Li Xu, Maitrayee Goswami, Mark E Zafereo, Steven I Sherman, Guojun Li, Erich M Sturgis, Jennifer R Wang
{"title":"Polygenic Score for Clinicopathologic Features and Survival Outcomes in Papillary Thyroid Carcinoma.","authors":"Sophie Li, Guibin Zheng, Li Xu, Maitrayee Goswami, Mark E Zafereo, Steven I Sherman, Guojun Li, Erich M Sturgis, Jennifer R Wang","doi":"10.1001/jamaoto.2024.3963","DOIUrl":"https://doi.org/10.1001/jamaoto.2024.3963","url":null,"abstract":"<p><strong>Importance: </strong>Genome-wide association studies have identified germline variants associated with the development of papillary thyroid carcinoma (PTC) that can be used to construct a polygenic score (PGS). It is important to determine whether patients with higher germline genetic risk, as summarized using PGS, present with more aggressive disease and/or develop worse clinical outcomes.</p><p><strong>Objective: </strong>To assess whether germline risk defined by PGS is associated with clinicopathologic features and survival outcomes for patients with PTC.</p><p><strong>Design, setting, and participants: </strong>This retrospective cohort study included patients with newly diagnosed PTC who presented to The University of Texas MD Anderson Cancer Center for treatment between 1999 and 2014, with a median follow-up of 12 years. Data were analyzed from December 2023 to April 2024.</p><p><strong>Exposure: </strong>Germline risk, as defined by PGS.</p><p><strong>Main outcomes and measures: </strong>Genomic DNA was extracted from buffy coat cells isolated from peripheral blood samples, and genotyping for germline polymorphisms was performed. Germline risk for PTC was estimated with a previously validated PGS calculated from 10 single-nucleotide variations identified through genome-wide association studies. Stage; PTC-specific survival, defined as the time from PTC diagnosis to death caused by PTC; and overall survival, defined as the time from PTC diagnosis to death by any cause, were analyzed.</p><p><strong>Results: </strong>A total of 366 patients were included in the study (261 women [71.3%]; mean [SD] age at diagnosis, 44.3 [13.8] years). There was a statistically significant association between higher PGS and multifocality (β [SE], 0.40 [0.23]; P = .045) and cervical lymph node involvement (N stage) (β [SE], 0.62 [0.35]; P = .009) at diagnosis. PGS was associated with PTC-specific survival (hazard ratio, 2.66; 95% CI, 1.03-6.85; P = .04), but this association was not independent of age and overall stage. There was not a statistically significant association between PGS and overall survival.</p><p><strong>Conclusions and relevance: </strong>Findings of this cohort study suggest that patients with a higher germline risk of PTC, as estimated by PGS, present with more aggressive clinicopathologic features. These results contribute to the current understanding of inherited risk in PTC and how germline variants could potentially contribute to disease presentation and clinical outcomes.</p>","PeriodicalId":14632,"journal":{"name":"JAMA otolaryngology-- head & neck surgery","volume":" ","pages":""},"PeriodicalIF":6.0,"publicationDate":"2024-11-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142728686","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Immune Checkpoint Inhibitors for Head and Neck Squamous Cell Carcinoma-Reply. 免疫检查点抑制剂治疗头颈部鳞状细胞癌--回复。
IF 6 1区 医学
JAMA otolaryngology-- head & neck surgery Pub Date : 2024-11-27 DOI: 10.1001/jamaoto.2024.3965
Eric V Mastrolonardo, Pablo Llerena, Joseph M Curry
{"title":"Immune Checkpoint Inhibitors for Head and Neck Squamous Cell Carcinoma-Reply.","authors":"Eric V Mastrolonardo, Pablo Llerena, Joseph M Curry","doi":"10.1001/jamaoto.2024.3965","DOIUrl":"https://doi.org/10.1001/jamaoto.2024.3965","url":null,"abstract":"","PeriodicalId":14632,"journal":{"name":"JAMA otolaryngology-- head & neck surgery","volume":" ","pages":""},"PeriodicalIF":6.0,"publicationDate":"2024-11-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142728677","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Patient and Caregiver Experience of Diagnosis, Treatment, and Living With Recurrent Oropharyngeal Cancer. 复发性口咽癌患者和护理者的诊断、治疗和生活经验。
IF 6 1区 医学
JAMA otolaryngology-- head & neck surgery Pub Date : 2024-11-21 DOI: 10.1001/jamaoto.2024.3757
Grainne Brady, Justin Roe, Vinidh Paleri, Pernilla Lagergren, Mary Wells
{"title":"Patient and Caregiver Experience of Diagnosis, Treatment, and Living With Recurrent Oropharyngeal Cancer.","authors":"Grainne Brady, Justin Roe, Vinidh Paleri, Pernilla Lagergren, Mary Wells","doi":"10.1001/jamaoto.2024.3757","DOIUrl":"10.1001/jamaoto.2024.3757","url":null,"abstract":"&lt;p&gt;&lt;strong&gt;Importance: &lt;/strong&gt;The management of recurrent oropharyngeal cancer (rOPC) is complex. Curative options carry considerable risk of morbidity with overall poor prognosis. Little data exist on function and quality of life (QoL) outcomes for noncurative treatments. Even less is known about patient and carer experiences of function and QoL change over time when undergoing curative or noncurative treatment(s) for rOPC.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Objective: &lt;/strong&gt;To investigate the patient and caregiver experience of diagnosis, treatment, and living with recurrent oropharyngeal cancer and changes to function/QoL.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Design, setting, and participants: &lt;/strong&gt;A longitudinal prospective and retrospective qualitative study was carried out at a specialist cancer center in the United Kingdom. Participants with a biopsy proven diagnosis of recurrent OPC and their caregivers were included. Participants were recruited between December 2022 and November 2023. Concurrent data analysis took took place between November 2023 and January 2024.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Exposure: &lt;/strong&gt;Curative salvage surgery or noncurative immunotherapy, chemotherapy, or clinical trials of investigational agents.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Main outcomes: &lt;/strong&gt;A framework-approach thematic analysis of semistructured, in-depth interviews.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Results: &lt;/strong&gt;Twenty-two patients and 7 caregivers were recruited. Demographic data was collected via medical record review. The longitudinal sample included 8 male and 2 female individuals, and the median age was 62 (range, 47-77) years. The retrospective sample included 11 male individuals and 1 female individual, and the median age was 64 (range, 59-70) years. Eleven participants (50%) underwent curative treatment, and 11 (50%) noncurative treatment.Treatments included salvage surgery, immunotherapy, chemotherapy, or clinical trials. Patients and their caregivers contextualize their experience of recurrent disease in their past experience of primary disease diagnosis and treatment. Patients want to survive and when the options to choose between are cure or functional outcomes impacting health-related QoL, cure appears to be favored. However, when cure is not an option, patients appear to want to survive as long as possible. However, as the prognosis gets shorter there appears to be a shift in priorities where function/QoL take precedence over survival.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Conclusions and relevance: &lt;/strong&gt;This qualitative study found that treatment decision-making is extremely complex in the setting of rOPC. Quite often, decisions are made based on what is perceived by health care professionals to be functionally \"too morbid\" with salvage surgery, or \"kinder\" with life-prolonging noncurative treatments. However, patients are not always fully involved in these decisions and so shared decision-making does not always happen. To facilitate shared decision-making and informed consent, patients need to be given clear and accurate information","PeriodicalId":14632,"journal":{"name":"JAMA otolaryngology-- head & neck surgery","volume":" ","pages":""},"PeriodicalIF":6.0,"publicationDate":"2024-11-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11583016/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142681992","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
A Large Sinonasal Mass in a Male Patient. 一名男性患者的巨大鼻窦肿块
IF 6 1区 医学
JAMA otolaryngology-- head & neck surgery Pub Date : 2024-11-21 DOI: 10.1001/jamaoto.2024.4005
Sei Y Chung, Parker Lawson, Anne C McLean
{"title":"A Large Sinonasal Mass in a Male Patient.","authors":"Sei Y Chung, Parker Lawson, Anne C McLean","doi":"10.1001/jamaoto.2024.4005","DOIUrl":"https://doi.org/10.1001/jamaoto.2024.4005","url":null,"abstract":"","PeriodicalId":14632,"journal":{"name":"JAMA otolaryngology-- head & neck surgery","volume":" ","pages":""},"PeriodicalIF":6.0,"publicationDate":"2024-11-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142681968","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Oncological Outcomes of Patients With Oral Potentially Malignant Disorders. 口腔潜在恶性疾病患者的肿瘤治疗效果。
IF 6 1区 医学
JAMA otolaryngology-- head & neck surgery Pub Date : 2024-11-21 DOI: 10.1001/jamaoto.2024.3719
Alessandro Villa, Michele Lodolo, Patrick Ha
{"title":"Oncological Outcomes of Patients With Oral Potentially Malignant Disorders.","authors":"Alessandro Villa, Michele Lodolo, Patrick Ha","doi":"10.1001/jamaoto.2024.3719","DOIUrl":"10.1001/jamaoto.2024.3719","url":null,"abstract":"<p><strong>Importance: </strong>Understanding the clinical course and malignant transformation rate of oral potentially malignant disorders (OPMDs)-including oral leukoplakia, oral erythroplakia, oral submucous fibrosis, and oral lichen planus-is crucial for early detection and improved survival rates in patients with oral cancer.</p><p><strong>Objective: </strong>To evaluate the progression of oral cancer from OPMDs using a large US electronic medical database.</p><p><strong>Design, setting, and participants: </strong>This retrospective cohort study used data from the University of California, San Francisco's PatientExploreR database between January 1973 and March 2024. Patients with oral leukoplakia, oral erythroplakia, oral submucous fibrosis, and oral lichen planus were identified using International Statistical Classification of Diseases and Related Health Problems, Tenth Revision, codes and keywords. Demographics, tobacco and alcohol use, HIV status, and other known risk factors for oral cancer were recorded to identify factors associated with malignant transformation. Logistic regression and descriptive analyses were used.</p><p><strong>Exposure: </strong>Diagnosis of oral leukoplakia, oral erythroplakia, oral submucous fibrosis, or oral lichen planus.</p><p><strong>Main outcomes and measures: </strong>Incidence of oral cancer, malignant transformation rate, median time to progression, and associations between demographics and risk factors and the development of oral cancer.</p><p><strong>Results: </strong>Among 4 225 251 individuals in the database, 4371 were diagnosed with oral cancer (median [IQR] age, 63 [53-71] years; 2610 [59.9%] male; 0.1% of the cohort), and 110 (2.5%) had a preceding OPMD. Oral leukoplakia was found in 1124 patients, with 94 (8.4%) undergoing malignant transformation (median [IQR] time to progression, 25 [7-129] months). HIV-positive patients with oral leukoplakia were more likely to develop oral cancer (odds ratio, 3.80; 95% CI, 1.35-10.70). Of 22 patients with oral erythroplakia, 11 (50.0%) developed oral cancer (median [IQR] time to progression, 3.7 [0.2-334] months). Those who smoked tobacco with oral erythroplakia showed a higher malignant transformation rate (odds ratio, 3.75; 95% CI, 0.54-26.05). Of the 78 patients with oral submucous fibrosis, 4 (5.1%) underwent malignant transformation (median [IQR] time to progression, 36 [36-48] months). Only 1 patient with oral lichen planus developed oral cancer after 5 years.</p><p><strong>Conclusions and relevance: </strong>This cohort study showed that OPMDs have notable but varying propensities to progress to oral cancer. Early detection and monitoring of OPMDs are crucial for improving patient outcomes. However, the risk, etiopathogenesis, and clinical presentation vary for each OPMD and should, therefore, be considered distinct diseases.</p>","PeriodicalId":14632,"journal":{"name":"JAMA otolaryngology-- head & neck surgery","volume":" ","pages":""},"PeriodicalIF":6.0,"publicationDate":"2024-11-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11583019/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142681971","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Technology Alone Cannot Promote Optimal Childhood Development-Why Cochlear Implantation Must Be Accompanied by Social Intervention. 仅靠技术无法促进儿童的最佳发育--为什么人工耳蜗植入必须辅以社会干预?
IF 6 1区 医学
JAMA otolaryngology-- head & neck surgery Pub Date : 2024-11-14 DOI: 10.1001/jamaoto.2024.3565
Stayce Camparo, Liz Sablich, Dana Suskind
{"title":"Technology Alone Cannot Promote Optimal Childhood Development-Why Cochlear Implantation Must Be Accompanied by Social Intervention.","authors":"Stayce Camparo, Liz Sablich, Dana Suskind","doi":"10.1001/jamaoto.2024.3565","DOIUrl":"https://doi.org/10.1001/jamaoto.2024.3565","url":null,"abstract":"","PeriodicalId":14632,"journal":{"name":"JAMA otolaryngology-- head & neck surgery","volume":" ","pages":""},"PeriodicalIF":6.0,"publicationDate":"2024-11-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142620860","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信